EP1514552A1 — Novel fused imidazole derivative
Assigned to Eisai R&D Management Co Ltd · Expires 2005-03-16 · 21y expired
What this patent protects
The present invention is related to compounds represented by the following formula, or salts or hydrates thereof <CHEM> wherein, T<1> represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic …
USPTO Abstract
The present invention is related to compounds represented by the following formula, or salts or hydrates thereof <CHEM> wherein, T<1> represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C1-6 alkyl group which may have one or more substituents, or such; Z<1> and Z<2> each independently represent a nitrogen atom or a group represented by the formula -CR<2>-; R<1> and R<2> independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such. <??>These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.